Suggested remit - To appraise the clinical and cost effectiveness of baloxavir marboxil within its marketing authorisation for treating influenza.
 
Status Proposed
Process STA 2018
ID number 1537

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 20 November 2019 - 18 December 2019

Project Team

Project lead Michelle Adhemar

Email enquiries


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance